[1] Yong SJ, Liu SL. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol, 2022; 32, e2315.
[2] Boscolo-Rizzo P, Borsetto D, Fabbris C, et al. Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg, 2020; 146, 729−32. doi:  10.1001/jamaoto.2020.1379
[3] Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 2021; 38, 101019. doi:  10.1016/j.eclinm.2021.101019
[4] Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine, 2020; 25, 100463. doi:  10.1016/j.eclinm.2020.100463
[5] Shah W, Hillman T, Playford ED, et al. Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ, 2021; 372, n136.
[6] Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open, 2021; 4, e2111417. doi:  10.1001/jamanetworkopen.2021.11417
[7] Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health, 2021; 6, e005427. doi:  10.1136/bmjgh-2021-005427
[8] Yusuf F, Fahriani M, Mamada SS, et al. Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: a systematic review and meta-analysis. F1000Res, 2021; 10, 301. doi:  10.12688/f1000research.52216.1
[9] Diem L, Fregolente-Gomes L, Warncke JD, et al. Fatigue in post-COVID-19 syndrome: clinical phenomenology, comorbidities and association with initial course of COVID-19. J Cent Nerv Syst Dis, 2022; 14, 11795735221102727.
[10] Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry, 2020; 7, 611−27. doi:  10.1016/S2215-0366(20)30203-0
[11] Scherer PE, Kirwan JP, Rosen CJ. Post-acute sequelae of COVID-19: a metabolic perspective. Elife, 2022; 11, e78200. doi:  10.7554/eLife.78200
[12] García-Abellán J, Fernández M, Padilla S, et al. Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol, 2022; 13, 920627. doi:  10.3389/fimmu.2022.920627
[13] Li DP, Liao XJ, Liu Z, et al. Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study. Emerg Microbes Infect, 2022; 11, 2680−8. doi:  10.1080/22221751.2022.2133639
[14] Arjun MC, Singh AK, Roy P, et al. Long COVID following omicron wave in Eastern India-A retrospective cohort study. J Med Virol, 2020.
[15] Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep, 2021; 11, 16144. doi:  10.1038/s41598-021-95565-8
[16] Wiemken TL, McGrath LJ, Andersen KM, et al. Coronavirus disease 2019 severity and risk of subsequent cardiovascular events. Clin Infect Dis, 2022; ciac661.
[17] Tana C, Bentivegna E, Cho SJ, et al. Long COVID headache. J Headache Pain, 2022; 23, 93. doi:  10.1186/s10194-022-01450-8
[18] Blomberg B, Mohn KGI, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med, 2021; 27, 1607−13. doi:  10.1038/s41591-021-01433-3
[19] Mullard A. Long COVID's long R&D agenda. Nat Rev Drug Discov, 2021; 20, 329−31. doi:  10.1038/d41573-021-00069-9
[20] Kondratiuk AL, Pillay TD, Kon OM, et al. A conceptual framework to accelerate the clinical impact of evolving research into long COVID. Lancet Infect Dis, 2021; 21, 756−7. doi:  10.1016/S1473-3099(21)00136-5
[21] WHO. A clinical CAS definition of post COVID condition by a Delphy consensus. World health Organization (WHO), 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.
[22] Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol, 2021; 93, 1013−22. doi:  10.1002/jmv.26368
[23] Centers for Disease Control and Prevention. Post-COVID conditions. 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. [2022-09-01].
[24] National Health Service. Long-term effects of coronavirus (long COVID). 2022. https://www.nhs.uk/conditions/coronavirus-covid-19/long-term-effects-of-coronavirus-long-covid/. [2022-10-24].
[25] Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis, 2022; 22, e102−7. doi:  10.1016/S1473-3099(21)00703-9
[26] Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al. Defining post-COVID symptoms (Post-Acute COVID, Long COVID, persistent Post-COVID): an integrative classification. Int J Environ Res Public Health, 2021; 18, 2621. doi:  10.3390/ijerph18052621
[27] Venkatesan P. NICE guideline on long COVID. Lancet Respir Med, 2021; 9, 129. doi:  10.1016/S2213-2600(21)00031-X
[28] Taquet M, Dercon Q, Luciano S, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273, 618 survivors of COVID-19. PLoS Med, 2021; 18, e1003773. doi:  10.1371/journal.pmed.1003773
[29] Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open, 2021; 4, e2128568. doi:  10.1001/jamanetworkopen.2021.28568
[30] Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med, 2021; 114, 428−42. doi:  10.1177/01410768211032850
[31] Yang XY, Hou C, Shen Y, et al. Two-year health outcomes in hospitalized COVID-19 survivors in China. JAMA Netw Open, 2022; 5, e2231790. doi:  10.1001/jamanetworkopen.2022.31790
[32] Estiri H, Strasser ZH, Brat GA, et al. Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Med, 2021; 19, 249. doi:  10.1186/s12916-021-02115-0
[33] Golla R, Vuyyuru S, Kante B, et al. Long-term gastrointestinal sequelae following COVID-19: a prospective follow-up cohort study. Clin Gastroenterol Hepatol, 2022.
[34] Office for National Statistics. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/7april2022. [2022-04-07].
[35] Förster C, Colombo MG, Wetzel AJ, et al. Persisting symptoms after COVID-19. Dtsch Arztebl Int, 2022; 119, 167−74.
[36] Morrow AJ, Sykes R, McIntosh A, et al. A multisystem, cardio-renal investigation of post-COVID-19 illness. Nat Med, 2022; 28, 1303−13. doi:  10.1038/s41591-022-01837-9
[37] Zarei M, Bose D, Nouri-Vaskeh M, et al. Long-term side effects and lingering symptoms post COVID-19 recovery. Rev Med Virol, 2022; 32, e2289.
[38] Pinzon RT, Wijaya VO, Jody AA, et al. Persistent neurological manifestations in long COVID-19 syndrome: a systematic review and meta-analysis. J Infect Public Health, 2022; 15, 856−69. doi:  10.1016/j.jiph.2022.06.013
[39] Choudhury A, Tariq R, Jena A, et al. Gastrointestinal manifestations of long COVID: a systematic review and meta-analysis. Therap Adv Gastroenterol, 2022; 15, 17562848221118403.
[40] Wulf Hanson S, Abbafati C, Aerts JG, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA, 2022; 328, 1604−15. doi:  10.1001/jama.2022.18931
[41] Ballering AV, van Zon SKR, Olde Hartman TC, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet, 2022; 400, 452−61. doi:  10.1016/S0140-6736(22)01214-4
[42] Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet, 2022; 399, 2263−4. doi:  10.1016/S0140-6736(22)00941-2
[43] Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open, 2022; 5, e2238804. doi:  10.1001/jamanetworkopen.2022.38804
[44] Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. Acta Paediatr, 2021; 110, 2208−11. doi:  10.1111/apa.15870
[45] Daitch V, Yelin D, Awwad M, et al. Characteristics of long-COVID among older adults: a cross-sectional study. Int J Infect Dis, 2022; 125, 287−93. doi:  10.1016/j.ijid.2022.09.035
[46] Pan CX, Zhang ZQ, Luo LY, et al. Cardiac T1 and T2 mapping showed myocardial involvement in recovered COVID-19 patients initially considered devoid of cardiac damage. J Magn Reson Imaging, 2021; 54, 421−8. doi:  10.1002/jmri.27534
[47] Nalbandian A, Desai AD, Wan EY. Post-COVID-19 condition. Annu Rev Med, 2023; 74.
[48] Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med, 2021; 27, 626−31. doi:  10.1038/s41591-021-01292-y
[49] Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One, 2020; 15, e0243882. doi:  10.1371/journal.pone.0243882
[50] Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect, 2021; 27, 258−63. doi:  10.1016/j.cmi.2020.09.052
[51] Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med, 2022; 28, 1706−14. doi:  10.1038/s41591-022-01909-w
[52] Ganesh R, Grach SL, Ghosh AK, et al. The female-predominant persistent immune dysregulation of the Post-COVID syndrome. Mayo Clin Proc, 2022; 97, 454−64. doi:  10.1016/j.mayocp.2021.11.033
[53] Rodriguez-Sanchez I, Rodriguez-Mañas L, Laosa O. Long COVID-19: the need for an interdisciplinary approach. Clin Geriatr Med, 2022; 38, 533−44. doi:  10.1016/j.cger.2022.03.005
[54] Kedor C, Freitag H, Meyer-Arndt L, et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun, 2022; 13, 5104. doi:  10.1038/s41467-022-32507-6
[55] Haffke M, Freitag H, Rudolf G, et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med, 2022; 20, 138. doi:  10.1186/s12967-022-03346-2
[56] Oatis D, Simon-Repolski E, Balta C, et al. Cellular and molecular mechanism of pulmonary fibrosis Post-COVID-19: focus on galectin-1, -3, -8, -9. Int J Mol Sci, 2022; 23, 8210. doi:  10.3390/ijms23158210
[57] Captur G, Moon JC, Topriceanu CC, et al. Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. eBioMedicine, 2022; 85, 104293. doi:  10.1016/j.ebiom.2022.104293
[58] Diem L, Schwarzwald A, Friedli C, et al. Multidimensional phenotyping of the post-COVID-19 syndrome: a Swiss survey study. CNS Neurosci Ther, 2022; 28, 1953−63. doi:  10.1111/cns.13938
[59] Lombardo MDM, Foppiani A, Peretti GM, et al. Long-term coronavirus disease 2019 complications in inpatients and outpatients: a one-year follow-up cohort study. Open Forum Infect Dis, 2021; 8, ofab384. doi:  10.1093/ofid/ofab384
[60] Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry, 2022; 9, 815−27. doi:  10.1016/S2215-0366(22)00260-7
[61] Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci, 2022; 434, 120162. doi:  10.1016/j.jns.2022.120162
[62] Lee JH, Yim JJ, Park J. Pulmonary function and chest computed tomography abnormalities 6-12 months after recovery from COVID-19: a systematic review and meta-analysis. Respir Res, 2022; 23, 233. doi:  10.1186/s12931-022-02163-x
[63] Alkodaymi MS, Omrani OA, Fawzy NA, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect, 2022; 28, 657−66. doi:  10.1016/j.cmi.2022.01.014
[64] Shuai HP, Chan JFW, Hu BJ, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B. 1.1. 529 Omicron. Nature, 2022; 603, 693−9. doi:  10.1038/s41586-022-04442-5
[65] van Doremalen N, Singh M, Saturday TA, et al. SARS-CoV-2 Omicron BA. 1 and BA. 2 are attenuated in rhesus macaques as compared to Delta. Sci Adv, 2022; 8, eade1860. doi:  10.1126/sciadv.ade1860
[66] Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature, 2022; 603, 700−5. doi:  10.1038/s41586-022-04462-1
[67] Venkataramani V, Winkler F. Cognitive deficits in long Covid-19. N Engl J Med, 2022; 387, 1813−5. doi:  10.1056/NEJMcibr2210069
[68] NHS. NHS to offer ‘long covid’ sufferers help at specialist centres. https://www.england.nhs.uk/2020/10/nhs-to-offer-long-covid-help/. [2020-10-07].
[69] National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence (NICE). 2020.
[70] Mazza MG, Palladini M, De Lorenzo R, et al. One-year mental health outcomes in a cohort of COVID-19 survivors. J Psychiatr Res, 2022; 145, 118−24. doi:  10.1016/j.jpsychires.2021.11.031
[71] Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry, 2021; 8, 130−40. doi:  10.1016/S2215-0366(20)30462-4
[72] Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry, 2021; 8, 416−27. doi:  10.1016/S2215-0366(21)00084-5
[73] Mazza MG, Palladini M, De Lorenzo R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun, 2021; 94, 138−47. doi:  10.1016/j.bbi.2021.02.021
[74] Mazza MG, Palladini M, Poletti S, et al. Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs, 2022; 36, 681−702. doi:  10.1007/s40263-022-00931-3
[75] Fernández-de-Las-Peñas C, Cuadrado ML, Gómez-Mayordomo V, et al. Headache as a COVID-19 onset symptom and post-COVID-19 symptom in hospitalized COVID-19 survivors infected with the Wuhan, Alpha, or Delta SARS-CoV-2 variants. Headache, 2022; 62, 1148−52. doi:  10.1111/head.14398
[76] Al-Kuraishy HM, Batiha GES, Faidah H, et al. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology, 2022; 30, 2017−26. doi:  10.1007/s10787-022-01027-6
[77] Bellan M, Baricich A, Patrucco F, et al. Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19. Sci Rep, 2021; 11, 22666. doi:  10.1038/s41598-021-01215-4
[78] Desgranges F, Tadini E, Munting A, et al. Post-COVID-19 syndrome in outpatients: a cohort study. J Gen Intern Med, 2022; 37, 1943−52. doi:  10.1007/s11606-021-07242-1
[79] Tran VT, Porcher R, Pane I, et al. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun, 2022; 13, 1812. doi:  10.1038/s41467-022-29513-z
[80] Hintschich CA, Fischer R, Hummel T, et al. Persisting olfactory dysfunction in post-COVID-19 is associated with gustatory impairment: results from chemosensitive testing eight months after the acute infection. PLoS One, 2022; 17, e0265686. doi:  10.1371/journal.pone.0265686
[81] Coles MJ, Masood M, Crowley MM, et al. It Ain't Over 'Til It's over: SARS CoV-2 and post-infectious gastrointestinal dysmotility. Dig Dis Sci, 2022; 67, 5407−15. doi:  10.1007/s10620-022-07480-1
[82] Ryan FJ, Hope CM, Masavuli MG, et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med, 2022; 20, 26. doi:  10.1186/s12916-021-02228-6